In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Philippe Gabriel Steg
Speaker
Philippe Gabriel Steg
Philippe Gabriel Steg Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

Speciality : Interventional Cardiology

P. Gabriel Steg, MD, FESC, FACC Born Feb 16, 1959 Université de Paris, INSERM U-1148, Département de Cardiologie, Hôpital Bichat Assistance Publique - Hôpitaux de Paris 46, rue Henri Huchard, 75877 Paris cedex 18, France Phone: +33 1 40 25 86 68, Fax : +33 1 40 25 88 65 E-mail: gabriel.steg@aphp.fr Affiliations - Chief, Department of Cardiology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, in Paris, France. - Vice President (in charge of research) of the board of Assistance Publique-Hôpitaux de Paris since 2018. - Professor of Cardiology at Université Paris - Diderot, since 1994. - Director of the “Clinical Research in Atherothrombosis” Research Team, INSERM Unit U1148, Paris - co-coordinator of the Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation and REmodeling). - Coordinator of the iVASC (InnoVations in Atherothrombosis SCience) RHU research consortium. - Chair of the FACT (French Alliance for cardiovascular Clinical Trials) academic resea

70 presentations from this speaker

Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD.

Event : ESC Congress 2020

  • Session : Clinical Update on Managing Hypertriglyceridaemia with Omega-3 Fatty Acid Icosapent Ethyl
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Amarin Pharma, Inc.

Hot Line REALITY.

Event : ESC Congress 2020

  • Session : Hot Line REALITY
  • Speaker : S Achenbach (Erlangen,DE), F Weidinger (Vienna,AT), P Steg (Paris,FR), M Roffi (Geneva,CH)

How to use antithrombotic therapy in chronic coronary syndromes.

Event : ESC Congress 2020

  • Session : How To Use Antithrombotic Therapy in Coronary Disease
  • Speaker : P Steg (Paris,FR)

Live Q&A and Adjourn.

Event : ESC Congress 2020

  • Session : Clinical Update on Managing Hypertriglyceridaemia with Omega-3 Fatty Acid Icosapent Ethyl
  • Speaker : P Steg (Paris,FR), B Nordestgaard (Herlev,DK)
  • Sponsored by Amarin Pharma, Inc.

Welcome and Introductions, Program Overview.

Event : ESC Congress 2020

  • Session : Clinical Update on Managing Hypertriglyceridaemia with Omega-3 Fatty Acid Icosapent Ethyl
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Amarin Pharma, Inc.

Combination therapy in CV risk reduction: what are we waiting for in dyslipidaemia management?

Event : ESC Congress 2019

  • Session : Hypercholesterolemia management - What will be our options after tomorrow?
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Mylan

Coronary and interventional research in Circulation.

Event : ESC Congress 2019

  • Session : The new Circulation: expanding frontiers
  • Speaker : P Steg (Paris,FR)
  • Organised with the Circulation Journal

Discussion

Event : ESC Congress 2019

  • Session : Confronting cardiovascular risk in patients with diabetes - Spotlight on dual antiplatelet therapy (EBAC Accredited)
  • Speaker : M Bonaca (Boston,US), P Steg (Paris,FR), H Darius (Berlin,DE), KK Ray (London,GB)
  • Supported by an unrestricted educational grant from AstraZeneca

Fish oil: it's all about triglycerides - PRO

Event : ESC Congress 2019

  • Session : Controversies in secondary prevention: treating residual risk
  • Speaker : P Steg (Paris,FR)

Insights and lessons from the ODYSSEY outcomes trial: which patients benefit most?

Event : ESC Congress 2019

  • Session : PCSK9i, changing practice in cardiology: the emerging story
  • Speaker : P Steg (Paris,FR)
  • Organised by PACE-CME, supported with an educational grant provided by Amgen, Draupnir Bio ApS, Sanofi-Regeneron & The Medicines Company

Myth of stable coronary artery disease: Learnings from clinical practice

Event : ESC Congress 2019

  • Session : Vascular protection - Which of your patients with chronic coronary artery disease will benefit?
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Bayer AG

Optimal acute medical treatment in acute coronary syndromes

Event : ESC Congress 2019

  • Session : Expert Advice - Best practice in acute coronary syndromes
  • Speaker : P Steg (Paris,FR)

Recent data and future direction on dual antiplatelet therapy in patients with diabetes

Event : ESC Congress 2019

  • Session : Confronting cardiovascular risk in patients with diabetes - Spotlight on dual antiplatelet therapy (EBAC Accredited)
  • Speaker : P Steg (Paris,FR)
  • Supported by an unrestricted educational grant from AstraZeneca

THEMIS/THEMIS-PCI

Event : ESC Congress 2019

  • Session : Meet the trialist - THEMIS/THEMIS PCI
  • Speaker : P Steg (Paris,FR), D Bhatt (Newton,US)

Welcome and introduction

Event : ESC Congress 2019

  • Session : Confronting cardiovascular risk in patients with diabetes - Spotlight on dual antiplatelet therapy (EBAC Accredited)
  • Speaker : P Steg (Paris,FR)
  • Supported by an unrestricted educational grant from AstraZeneca

ACS pharmacotherapy studies in Circulation

Event : ESC Congress 2018

  • Session : The New Circulation
  • Speaker : P Steg (Paris,FR)
  • Journal Circulation

Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: post- ACS patients with elevated atherogenic lipid levels

Event : ESC Congress 2018

  • Session : Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Sanofi and Regeneron

P2Y12 pretreatment in NSTE-ACS is needed

Event : ESC Congress 2018

  • Session : Dual antiplatelet therapy and PCI - Important controversies
  • Speaker : P Steg (Paris,FR)

P2Y12 pretreatment in NSTE-ACS is needed - Rebuttal.

Event : ESC Congress 2018

  • Session : Dual antiplatelet therapy and PCI - Important controversies
  • Speaker : P Steg (Paris,FR)

Roundtable: learnings in practice

Event : ESC Congress 2018

  • Session : Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data
  • Speaker : P Steg (Paris,FR), AM Zeiher (Frankfurt,DE)
  • Sponsored by Sanofi and Regeneron

What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us?

Event : ESC Congress 2018

  • Session : PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Sanofi US and Regeneron Pharmaceuticals

Coronary and interventional research in Circulation.

Event : ESC Congress 2017

  • Session : The new Circulation: expanding frontiers
  • Speaker : P Steg (Paris,FR)
  • Joint with Circulation

Discussion - Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice.

Event : ESC Congress 2017

  • Session : Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice (EBAC Accredited)
  • Speaker : P Steg (Paris,FR), DJ Angiolillo (Jacksonville,US), S James (Uppsala,SE), R Mehran (New York,US)
  • Sponsored by AstraZeneca

Interactive discussions and questions - Vascular protection in CAD and PAD through factor Xa inhibition... The COMPASS study.

Event : ESC Congress 2017

  • Session : Vascular protection in coronary artery disease (CAD) and peripheral artery disease (PAD) through factor Xa inhibition... The COMPASS study
  • Speaker : D Bhatt (Newton,US), P Steg (Paris,FR), J Eikelboom (Hamilton,CA), SJ Connolly (Hamilton,CA), S Yusuf (Hamilton,CA)
  • Sponsored by Bayer AG

Open questions - Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice.

Event : ESC Congress 2017

  • Session : Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice (EBAC Accredited)
  • Speaker : P Steg (Paris,FR), DJ Angiolillo (Jacksonville,US)
  • Sponsored by AstraZeneca

Session close - Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice.

Event : ESC Congress 2017

  • Session : Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice (EBAC Accredited)
  • Speaker : P Steg (Paris,FR)
  • Sponsored by AstraZeneca

Update and future of secondary prevention

Event : ESC Congress 2017

  • Session : Predicting and preventing acute events in patients with stable coronary artery disease
  • Speaker : P Steg (Paris,FR)

Welcome and introduction - Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice.

Event : ESC Congress 2017

  • Session : Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice (EBAC Accredited)
  • Speaker : P Steg (Paris,FR)
  • Sponsored by AstraZeneca

Welcome and introduction - Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice.

Event : ESC Congress 2017

  • Session : Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice (EBAC Accredited)
  • Speaker : P Steg (Paris,FR)
  • Sponsored by AstraZeneca

What are the unmet medical needs in secondary cardiovascular disease prevention?

Event : ESC Congress 2017

  • Session : Atherosclerosis and secondary cardiovascular disease prevention: inflammation and low density lipoprotein (LDL)-cholesterol
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Novartis Pharma AG

Which patients with CAD or PAD are at the highest risk of cardiovascular events... What do the registries teach us.

Event : ESC Congress 2017

  • Session : Exploring vascular protection in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) through the potential of factor Xa inhibition... The COMPASS study
  • Speaker : P Steg (Paris,FR), D Bhatt (Newton,US)
  • Sponsored by Bayer AG

Balancing efficacy and safety of antithrombotics

Event : ESC Congress 2016

  • Session : The new Circulation: looking back and moving forward
  • Speaker : P Steg (Paris,FR)
  • Joint with Circulation

Discussion - Optimising antiplatelet therapy from first medical contact to discharge.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : D Capodanno (Catania,IT), C Hamm (Bad Nauheim,DE), S James (Uppsala,SE), P Steg (Paris,FR), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Discussion - The patient journey after an acute coronary syndrome - A clinical case study.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : D Capodanno (Catania,IT), C Hamm (Bad Nauheim,DE), S James (Uppsala,SE), P Steg (Paris,FR), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Discussion - Who, when and why - The rationale to treat beyond 12 months.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : D Capodanno (Catania,IT), C Hamm (Bad Nauheim,DE), S James (Uppsala,SE), P Steg (Paris,FR), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Open questions - The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : P Steg (Paris,FR), S James (Uppsala,SE), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Optimal DAPT after DES - Discussant review.

Event : ESC Congress 2016

  • Session : Hot Line preventive strategies 1
  • Speaker : P Steg (Paris,FR)

Optimising antiplatelet therapy from first medical contact to discharge.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : P Steg (Paris,FR)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Session close - The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : P Steg (Paris,FR)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Usually statins and ezetimibe are enough

Event : ESC Congress 2016

  • Session : Improving secondary prevention of atherosclerotic disease
  • Speaker : P Steg (Paris,FR)
  • Joint with the International Society of Cardiovascular Pharmacotherapy

Antiplatelet management in patients undergoing coronary interventions - Pre-treatment is always better - PRO

Event : ESC Congress 2015

  • Session : Controversies in antiplatelet management in patients undergoing coronary interventions
  • Speaker : P Steg (Paris,FR)

Atherothrombotic disease: lessons from real life (post Myocardial Infarction (MI)) .

Event : ESC Congress 2015

  • Session : Prevention of atherothrombotic events: what’s the new evidence?
  • Speaker : P Steg (Paris,FR)
  • Sponsored by MSD

Closing - Prevention of atherothrombotic events: what’s the new evidence?

Event : ESC Congress 2015

  • Session : Prevention of atherothrombotic events: what’s the new evidence?
  • Speaker : P Steg (Paris,FR), D Morrow (Boston,US)
  • Sponsored by MSD

ELIXA: Discussant review.

Event : ESC Congress 2015

  • Session : Hot Line III - Diabetes mellitus/Pharmacology
  • Speaker : P Steg (Paris,FR)

Future direction for research in bleeding prediction, prevention and management.

Event : ESC Congress 2015

  • Session : Bleeding and ischaemic events in PCI patients: prediction, prevention and management
  • Speaker : P Steg (Paris,FR)

Opening by the chairs - Prevention of atherothrombotic events: what’s the new evidence?

Event : ESC Congress 2015

  • Session : Prevention of atherothrombotic events: what’s the new evidence?
  • Speaker : P Steg (Paris,FR), D Morrow (Boston,US)
  • Sponsored by MSD

Panel discussion & Q&A - Prevention of atherothrombotic events: what’s the new evidence?

Event : ESC Congress 2015

  • Session : Prevention of atherothrombotic events: what’s the new evidence?
  • Speaker : P Steg (Paris,FR), D Morrow (Boston,US), JM Morais (Leiria,PT), GM De Ferrari (Pavia,IT)
  • Sponsored by MSD

Practical issues for use of oral factor Xa inhibition following acute coronary syndrome: risk stratification, patient selection, timing of therapy, bleeding risk reduction, stented patients and long-term management.

Event : ESC Congress 2015

  • Session : Practical dimensions of NOAC-based management of stroke prevention in Atrial Fibrillation (AF) and acute coronary syndrome
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Bayer HealthCare

Pre-treatment is always better - REBUTTAL PRO.

Event : ESC Congress 2015

  • Session : Controversies in antiplatelet management in patients undergoing coronary interventions
  • Speaker : P Steg (Paris,FR)

Welcome and session objectives - Dual anti-platelet therapy in 2015 – Reviewing the evidence.

Event : ESC Congress 2015

  • Session : Dual anti-platelet therapy in 2015 – Reviewing the evidence
  • Speaker : P Steg (Paris,FR)
  • Organised by The Sahlgrenska Academy - Goteborg University Course Director: Karl Swedberg Supported by an unrestricted educational grant from AstraZeneca

What still needs to be clarified in stable angina management?

Event : ESC Congress 2015

  • Session : Appraisal of therapies in angina management
  • Speaker : P Steg (Paris,FR)
  • Organised by University Hospital Zurich Course Director: Thomas Luscher Supported by an unrestricted educational grant from SERVIER

Discussion - Early initiation of antiplatelet therapy.

Event : ESC Congress 2014

  • Session : Antiplatelet therapy in high-risk patients with acute coronary syndromes – Current evidence and future directions
  • Speaker : P Steg (Paris,FR)
  • Organised by The Sahlgrenska Academy - Goteborg University / Course Director: Karl Swedberg / Supported by an unrestricted educational grant from AstraZeneca

Early initiation of antiplatelet therapy - Recommendations and current practice.

Event : ESC Congress 2014

  • Session : Antiplatelet therapy in high-risk patients with acute coronary syndromes – Current evidence and future directions
  • Speaker : P Steg (Paris,FR)
  • Organised by The Sahlgrenska Academy - Goteborg University / Course Director: Karl Swedberg / Supported by an unrestricted educational grant from AstraZeneca

Panel discussion - Heart rate reduction: questions and answers in the management of coronary artery disease.

Event : ESC Congress 2014

  • Session : Heart rate reduction: questions and answers in the management of coronary artery disease
  • Speaker : M Tendera (Katowice,PL), R Ferrari (Ferrara,IT), I Ford (Glasgow,GB), K Fox (London,GB), P Steg (Paris,FR), J Tardif (Montreal,CA)
  • Sponsored by SERVIER

PLATO: impact on the management of acute coronary syndromes and the future with PARTHENON.

Event : ESC Congress 2014

  • Session : Back in Barcelona with PLATO: 5 years of science, guidelines, practice and controversies
  • Speaker : P Steg (Paris,FR)
  • Sponsored by AstraZeneca

Practical issues for use of oral factor Xa inhibition following ACS: risk stratification, patient selection,timing of therapy, bleeding risk reduction, stented patients and long-term management.

Event : ESC Congress 2014

  • Session : New advances and practical dimensions of optimizing management of acute coronary syndrome: evidence-based use of oral factor Xa inhibition to improve outcomes in patients with acute coronary syndrome (ACS) - Risk stratification, patient selection, and clinical pearls for oral factor Xa-based management
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Bayer HealthCare

Cardiovascular outcomes studies in type 2 diabetes – Leading a new era?

Event : ESC Congress 2013

  • Session : Redefining the future for cardiovascular disease management in type 2 diabetes
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Bristol-Myers Squibb and AstraZeneca

CLARIFY: Impact of angina and ischemia on outcomes in stable CAD

Event : ESC Congress 2013

  • Session : Registry Hot Line: Registries on prevention and treatment
  • Speaker : P Steg (Paris,FR)

Discussion - Management of hyperlipidemia: what does the future hold?

Event : ESC Congress 2013

  • Session : Management of hyperlipidemia: what does the future hold?
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Sanofi and Regeneron

Introduction and welcome.

Event : ESC Congress 2013

  • Session : Management of hyperlipidemia: what does the future hold?
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Sanofi and Regeneron

Panel discussion: redefining the future for cardiovascular disease management in type 2 diabetes

Event : ESC Congress 2013

  • Session : Redefining the future for cardiovascular disease management in type 2 diabetes
  • Speaker : L Ryden (Stockholm,SE), J Davidson (Dallas,US), E Mannucci (Firenze,IT), L Leiter (Toronto,CA), P Steg (Paris,FR)
  • Sponsored by Bristol-Myers Squibb and AstraZeneca

State of the Art lecture - Current guidelines and future possibilities in acute coronary syndromes

Event : ESC Congress 2013

  • Session : State of the Art - Acute coronary syndromes - current guidelines and future prospects
  • Speaker : P Steg (Paris,FR)

TAO: Otamixaban in non-ST-segment elevation acute coronary syndrome patients undergoing a planned invasive strategy

Event : ESC Congress 2013

  • Session : Hot Line I: Late Breaking Trials on Thrombosis
  • Speaker : P Steg (Paris,FR)

The pivotal roles of insulin resistance, glycemic target goal attainment, and lipid profile management in the setting of T2D: identifying optimal cardiometabolic target goals to maximize cardiovascular risk reduction in patients with ACS and CAD.

Event : ESC Congress 2013

  • Session : New frontiers, novel mechanisms, and evolving paradigms for optimizing cardiovascular risk reduction in patients with type 2 diabetes and acute coronary syndrome
  • Speaker : P Steg (Paris,FR)
  • Sponsored by Roche

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are